Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial

Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial

Objectives: In 2017, the World Health Organisation (WHO) pre-qualified a single-dose typhoid conjugate vaccine (TCV) and identified TCV co-administration studies as a research priority. Accordingly, we tested co-administration of Typbar TCV® (Bharat Biotech International) with measles-rubella (MR) a...

Full description

Bibliographic Details
Main Authors: Sodiomon B. Sirima, Alphonse Ouedraogo, Nouhoun Barry, Mohamadou Siribie, Alfred Tiono, Issa Nébié, Amadou Konaté, Gloria Damoaliga Berges, Amidou Diarra, Moussa Ouedraogo, Edith C. Bougouma, Issiaka Soulama, Alimatou Hema, Shrimati Datta, Yuanyuan Liang, Elizabeth T. Rotrosen, J. Kathleen Tracy, Leslie P. Jamka, Jennifer J. Oshinsky, Marcela F. Pasetti, Kathleen M. Neuzil, Matthew B. Laurens
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:International Journal of Infectious Diseases
Subjects:
Typhoid conjugate vaccine
Typhoid fever
Burkina Faso
Yellow fever vaccine
Coadministration
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971221004616

Internet

http://www.sciencedirect.com/science/article/pii/S1201971221004616

Similar Items